Osimertinib vs Pembrolizumab
Osimertinib vs Pembrolizumab: Overview
This comparison examines the pharmacological differences between Osimertinib and Pembrolizumab.
Mechanism of Action
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Osimertinib — 48 hours; Pembrolizumab — 26 days.
Chemical Properties
Molecular Formula: Osimertinib — C28H33N7O2.
Molecular Weight: Osimertinib — 499.6050 g/mol.
Type: Osimertinib — Small molecule; Pembrolizumab — Antibody.